Facial cosmetic procedures become popular for people with a desire to have a younger appearance, and cosmetic technology has developed rapidly over the past several decades. However, increasing complications related to cosmetic injections have been reported, and infection is one of the most serious problems and can cause anxiety and facial injury. We here report a case of Majocchi's granuloma (MG) caused by Trichophyton rubrum after facial injection of hyaluronic acid.

A 37-year-old woman presented to our hospital with a history of red papules, nodules, and abscesses on her left zygomatic arch for 2 mo. She had received a cosmetic injection of hyaluronic acid on the left side of her face prior to the appearance of the lesions. MG caused by Trichophyton rubrum after facial injection of hyaluronic acid was diagnosed based on morphology and molecular biological identification. In vitro antifungal susceptibility testing was conducted according to the Clinical and Laboratory Standards Institute M38-A2 method. Minimal inhibitory concentrations were used to evaluate the antifungal susceptibility. The antifungal agents and their minimal inhibitory concentrations for the strain were terbinafine (< 0.5 μg/mL), itraconazole (0.06 μg/mL), amphotericin B (0.25 μg/mL), fluconazole (32 μg/mL), voriconazole (0.125 μg/mL), posaconazole (0.125 μg/mL), and isavuconazole (0.06 μg/mL). We initially administered 250 mg/d oral terbinafine for 2 mo, but the patient still had painful papules, nodules and abscesses on her face. Then, we adjusted the treatment to itraconazole 400 mg/d for 8 wk based on the in vitro antifungal susceptibility testing results. The skin lesions improved significantly, and there was no recurrence during follow-up.

This case revealed that facial injection of hyaluronic acid may cause serious MG. Antifungal susceptibility testing should be considered in the treatment of MG caused by Trichophyton rubrum.

With the increasing popularity of cosmetic injections, such as hyaluronic acid and botulinum injection, an increasing number of related complications after cosmetic injections have been reported recently[1,2]. Hyaluronic acid fillers may cause early and immediate adverse reactions, such as needle marks or pinpoint bleeding, erythema or redness, swelling and edema, pain, tenderness, and ecchymosis, in 0.05% to 2% of cases[3]. Delayed adverse reactions, including hypersensitivity and granulomatous reaction, are reported to occur in up to 0.6% of cases[4].

Among the complications, the risk of infection increased by improper disinfection of the patient’s skin, incorrect injection techniques, decreased general immunity, and the presence of pathogens[5]. To date, the difficulty in the study of Majocchi's granuloma (MG) from an infection lies in the accurate diagnosis of the organism and the identification of susceptibility to antifungal testing in vitro, which are important to guide the treatment of MG caused by pathogens. We report a case of MG caused by Trichophyton rubrum infection after facial injection of hyaluronic acid.

A diagnosis of MG caused by Trichophyton rubrum after facial injection of hyaluronic acid was made based on the cosmetic injection history, the presence of skin lesions, morphological and molecular biological results and histological examination.

The patient was initially started on terbinafine 250 mg/d for 2 mo, but the painful papules, nodules and abscesses on her face did not improve. Then, we adjusted the treatment to itraconazole 400 mg/d for 8 wk based on the in vitro antifungal susceptibility testing results.

The skin lesions improved significantly after treatment with itraconazole 400 mg/d for 8 wk, and there was no recurrence during the follow-up (Figure 1B).

Facial cosmetic procedures become popular because of people’s desire for a younger appearance and the development of cosmetic technology over the past several decades[7]. To date, hyaluronic acid is reported to be safe and well tolerated and has become one of the most important fillers for cosmetic rejuvenescence. However, complications, such as infection, anaphylaxis and embolism after facial injection, are more common as more cosmetic procedures are performed, especially cosmetic injections administered in small unlicensed clinics.

Dermatophytes are widespread and are among the most common cause of superficial fungal infections worldwide[8]. Trichophyton rubrum is currently recognized as the most common fungal pathogen among dermatophyte infections and is often intractable. MG is an inflammatory and granulomatous dermatophyte infection, and the main pathogen that causes MG is Trichophyton rubrum. It has been reported that the number of cases of MG has been rising over the years[9]. In the present case, the patient and her family members had no history of dermatophytosis. She had no contact with others except her family members after undergoing cosmetic injection of hyaluronic acid. She presented with multiple painful abscesses on the left side of her face, and the lesion was located at the site of cosmetic injection. A contaminant from the operating room of the unqualified clinic where the injection procedure was performed likely caused the Trichophyton rubrum infection.

Systemic treatment of Trichophyton rubrum infection mainly includes allylamines, azoles, polyenes and hydroxypyridones. In general, terbinafine (250 mg/d), as a representative allylamine antifungal agent, is the preferred systemic antifungal drug for the treatment of MG and is used in 40.8% of cases. When the infectious agent cannot be isolated, terbinafine should be the first-choice treatment because organisms resistant to itraconazole or griseofulvin have been reported to be responsive to terbinafine. Wang et al[10] presented two cases of MG with different clinical features. Both patients had satisfactory relief after treatment with terbinafine. Su et al[11] also successfully treated a case of Trichophyton rubrum infection characterized by MG and deeper dermatophytosis with oral terbinafine 250 mg/d, and the patient's skin lesion disappeared. However, terbinafine-resistant strains have been found in cases of drug-resistant dermatophyte infection, including Trichophyton rubrum infection, in recent years[12-14]. Other systemic antifungal drugs to treat dermatophyte infections include itraconazole, griseofulvin, ketoconazole, voriconazole, and posaconazole[15-19]. Gupta et al[20] found that two pulses of oral itraconazole therapy appeared to be effective in the treatment of MG. In the case we reported here, the patient was unresponsive to terbinafine and was successfully treated with itraconazole, which should indicate the need for doctors to select treatment agents by performing in vitro antifungal susceptibility testing.

Mycology examinations are important to identify the causative agent, especially the type of invasive dermatophytosis, and can determine the treatment. In the case of MG and other invasive dermatophyte infections that are difficult to treat, such as mycetoma and pseudomycetoma, terbinafine is the preferred choice for treatment. Therefore, it is of key importance to accurately diagnose the disease-causing agents, especially in immunocompromised patients. In addition, cosmetic injections should be given in a sterile environment, and people should be aware of the risk of fungal infection in the pursuit of beauty.

This case revealed that facial injection of hyaluronic acid may cause serious MG. Antifungal susceptibility testing should be conducted to help select proper agents during clinical treatment.